Russell Frank Company’s Achillion Pharmaceuticals ACHN Stock Holding History

Russell Frank Company’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$146K	Buy	+18,892	New	+$138K	﹤0.01%	2737
2015 Q1	–	Sell	-141,224	Closed	-$1.74M	–	3081
2014 Q4	$1.74M	Sell	141,224 -18,608	-12%	-$227K	﹤0.01%	1866
2014 Q3	$1.59M	Buy	+159,832	New	+$1.48M	﹤0.01%	1853
2013 Q4	–	Sell	-8,569	Closed	-$62K	–	3190
2013 Q3	$62K	Buy	8,569 +145	+2%	+$994	﹤0.01%	3049
2013 Q2	$69K	Buy	+8,424	New	+$64.3K	﹤0.01%	2822

Other funds holding ACHN

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Russell Frank Company's ACHN Position: Q1 2016 in Review

Russell Frank Company opened a new position in Achillion Pharmaceuticals (ACHN) in Q1 2016: 18,892 shares worth $146K. The stake represents ﹤0.01% of the portfolio and ranks #2737 among its holdings. This is a return to the name: Russell Frank Company previously reported a position in ACHN as recently as Q4 2014.

Russell Frank Company first reported a position in ACHN in Q2 2013 and has held it in 5 quarters since. The position peaked at $1.74M in Q4 2014. 153 funds tracked by Wall St. Rank hold ACHN as of Q1 2016.

Russell Frank Company held 18,892 shares of Achillion Pharmaceuticals worth $146K as of Q1 2016.
Achillion Pharmaceuticals was a new Russell Frank Company position in Q1 2016.
Achillion Pharmaceuticals made up ﹤0.01% of Russell Frank Company's portfolio in Q1 2016, its #2737 holding.
Russell Frank Company first reported a position in Achillion Pharmaceuticals in Q2 2013 and has held it in 5 quarters since.
Russell Frank Company's Achillion Pharmaceuticals position peaked at $1.74M in Q4 2014.
153 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.